World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
Austria
2026

D-Index & Metrics

Best Scientists

D-Index
175
Citations
167963
World Ranking
704
National Ranking
3

Medicine

D-Index
179
Citations
173744
World Ranking
373
National Ranking
2

Research.com Recognitions

  • 2026 - Research.com Medicine in Austria Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in Austria Leader Award
  • 2023 - Research.com Immunology in Austria Leader Award
  • 2023 - Research.com Medicine in Austria Leader Award
  • 2022 - Research.com Immunology in Austria Leader Award
  • 2022 - Research.com Medicine in Austria Leader Award
  • 2020 - City of Vienna Prize for Science
  • 2007 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology

Overview

Josef S. Smolen is affiliated with the Medical University of Vienna in Austria. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with particular emphasis on Rheumatology and Immunology as subfields. Additional research subfields include Hematology, Genetics, and Pathology and Forensic Medicine.

The focus of their work covers multiple topics related to autoimmune and inflammatory conditions. These include Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, Psoriasis: Treatment and Pathogenesis, Biosimilars and Bioanalytical Methods, Spondyloarthritis Studies and Treatments, Systemic Lupus Erythematosus Research, and Chronic Lymphocytic Leukemia Research.

Josef S. Smolen has published extensively in key academic journals, with frequent appearances in:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • RMD Open
  • Arthritis & Rheumatology
  • Arthritis Research & Therapy

Among their recent papers are:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, 2020, Annals of the Rheumatic Diseases
  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update, 2022, Annals of the Rheumatic Diseases

These publications have been cited frequently, with thousands of citations highlighting their impact within the scientific community.

Frequent collaborators of Josef S. Smolen include:

  • Daniel Aletaha
  • Andreas Kerschbaumer
  • Laure Gossec
  • Kevin Winthrop
  • Maarten de Wit

Throughout their career, Josef S. Smolen has received recognition such as the City of Vienna Prize for Science in 2020. Additionally, they were elected to the German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina in 2007 for contributions to Internal Medicine and Dermatology.

Best Publications

  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

    Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

    P E Lipsky;D M van der Heijde;E W St Clair;D E Furst

  • 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Martin Aringer;Karen Costenbader;David Daikh;Ralph Brinks

  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

    R Maini;E W St Clair;F Breedveld;D Furst

  • Treating rheumatoid arthritis to target: recommendations of an international task force

    Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

  • Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

    M J Elliott;R N Maini;M Feldmann;J R Kalden

  • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

    Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen

  • 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

    Antonis Fanouriakis;Myrto Kostopoulou;Alessia Alunno;Martin Aringer

  • Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

    Claudio Vitali;Stefano Bombardieri;Haralampos M. Moutsopoulos;Genesio Balestrieri

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

    Josef S Smolen;Andre Beaulieu;Andrea Rubbert-Roth;Cesar Ramos-Remus

  • Diagnosis and Management of Rheumatoid Arthritis: A Review.

    Daniel Aletaha;Josef S Smolen

  • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk

  • Dickkopf-1 is a master regulator of joint remodeling

    Danielle Diarra;Marina Stolina;Karin Polzer;Jochen Zwerina

  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

    E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  • New therapies for treatment of rheumatoid arthritis

    Josef S Smolen;Daniel Aletaha;Marcus Koeller;Michael H Weisman

  • EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    W. Zhang;M. Doherty;B. F. Leeb;L. Alekseeva

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados

Frequent Co-Authors

Daniel Aletaha
Daniel Aletaha Medical University of Vienna
Paul Emery
Paul Emery University of Leeds
Robert Landewé
Robert Landewé University of Amsterdam
Laure Gossec
Laure Gossec Sorbonne University
Martin Aringer
Martin Aringer TU Dresden
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Tore K. Kvien
Tore K. Kvien University of Oslo
Gerd R. Burmester
Gerd R. Burmester Charité - University Medicine Berlin
Maxime Dougados
Maxime Dougados Hôpital Cochin
Günter Steiner
Günter Steiner Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not sure if becoming a doctor is right for you, there are several related online degrees and career pathways to consider. Education in fields like health information management, medical billing and coding, or nursing can provide alternative opportunities in the medical sector, often with more flexible entry requirements and career advancement potential.

For those drawn to administrative or data-driven roles, pursuing a him degree online can open doors to health information management, where professionals manage medical records and patient data.

Another in-demand option is working in medical billing and coding. Understanding how much is medical billing and coding school is essential for budgeting your education and entering this rapidly growing field.

Nursing is a rewarding and versatile profession with a variety of online programs. Those seeking an advanced role might explore the cheapest nurse practitioner programs. Alternatively, students looking for foundational nursing education can compare the cheapest online bsn programs to find affordable paths to a Bachelor of Science in Nursing.

These online options offer flexibility, lower costs, and swift entry into the healthcare workforce—ideal for those looking to make a difference without following the traditional path to becoming a doctor.

Best Scientists Citing Josef S. Smolen

Trending Scientists